Wells Fargo analyst Derek Archila raised the firm’s price target on Ascendis Pharma to $137 from $134 and keeps an Overweight rating on the shares. The firm thinks the upcoming NDA re-submission for TransCon PTH puts it on track for a 2024 approval. Wells remains bullish on its market opportunity and focus will shift from its approvability to the sales ramp next year – this is a launch to own, in the firm’s view.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ASND:
- Ascendis Pharma Reports Third Quarter 2023 Financial Results
- ASND Earnings this Week: How Will it Perform?
- Ascendis Pharma Announces Timing of Third Quarter 2023 Financial Results and TransCon PTH NDA Resubmission
- Ascendis Pharma to resubmit NDA for TransCon PTH before mid-November
- Ascendis Pharma presents updated, new TransCon IL-2 data